Nuvectis Pharma Suspends ATM Offering Prospectus; Reduces to $5M

Nuvectis Pharma, Inc. announced the suspension of its Sales Agreement Prospectus, which allowed the company to sell shares of its common stock through Leerink Partners LLC. The company reduced the available amount for sales under the prospectus to $5 million. While the prospectus is suspended, the underlying Sales Agreement remains active, and no further sales will occur until a new prospectus or registration statement is filed.